Vonjo was also shown to improve overall survival in patients with myelofibrosis treated with Vonjo in the real-world setting. Improvements in thrombocytopenia and anemia were observed in patients with ...

Myelofibrosis (MF) is a complex and clinically heterogeneous myeloproliferative neoplasm, presenting significant challenges for patient care and clinical decision making. Although global guidelines ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Lower platelet count was identified as a significant predictor for ruxolitinib-induced moderate or ...

Please provide your email address to receive an email when new articles are posted on . Navitoclax plus ruxolitinib led to improvement in spleen volume reduction in patients with untreated ...

New translational data suggests potential disease-modifying effects following treatment with pelabresib of both first-line and ruxolitinib-relapsed/refractory ...

– Encouraging Data Observed in Phase 1 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis, Including Activity Across Three Key Efficacy Endpoints of Spleen Volume ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Jain: Our topic ...

Jaktinib significantly improved spleen volume reduction rates compared with hydroxyurea in intermediate- to high-risk myelofibrosis. Jaktinib, a novel JAK/ACVR1 inhibitor, significantly improved rates ...

– At Week 24, 60mg of Selinexor in Combination with Ruxolitinib Achieved: 92% SVR35 and 78% TSS50 in Efficacy Evaluable Population, 79% SVR35 and 58% TSS50 in Intent to Treat Population – – Rapid, ...

MorphoSys announced positive topline results from its phase 3 trial of pelabresib in frontline myelofibrosis, nearly doubling spleen volume reduction (the primary endpoint) compared to placebo.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced ...